Lilly's $2.3B Acquisition Yields Bone Marrow Cancer Breakthrough

Eli Lilly and Company has reported promising early-stage clinical results for AJ1-11095, an investigational agent acquired through its $2.3 billion purchase of biotech firm Ajax Therapeutics. Data unveiled at the European Haematology Association (EHA) Annual Meeting 2026 indicate that the drug not only alleviates disease symptoms in patients with myelofibrosis — a rare and aggressive bone marrow malignancy — but may also reduce the underlying cancer burden at the genetic level, a capability that existing approved therapies have not demonstrated.

The findings carry particular significance given that the trial enrolled exclusively patients whose disease had progressed on or proved refractory to currently available treatments, a population with historically poor outcomes and limited therapeutic recourse.

Disease Background and the Limitations of Existing Therapy

Myelofibrosis is a clonal bone marrow disorder characterised by progressive fibrosis, impaired haematopoiesis, and constitutional symptoms including severe fatigue, bone pain, and night sweats. Pathological splenomegaly — the enlargement of the spleen as it assumes erythropoietic function — is a cardinal feature and a primary source of patient morbidity.

For more than a decade, ruxolitinib (Jakafi, Incyte Corporation) has served as the standard of care, functioning as a JAK1/JAK2 inhibitor that suppresses overactive kinase signalling. While effective in managing symptoms, ruxolitinib and related agents do not eliminate the malignant clone. Over time, the disease adapts: secondary mutations emerge, JAK-STAT pathway reactivation occurs, and patients develop resistance. At that point, approved second-line options are scarce and response rates are low.

A Novel Mechanism: Targeting the Inactive Kinase Conformation

AJ1-11095 is differentiated from existing JAK inhibitors by its binding mechanism. Rather than competing with ATP at the active site of the JAK2 kinase during its active state, the compound is engineered to bind selectively to the inactive, or “type II,” conformation of the protein. By engaging the kinase while it is structurally quiescent, the drug locks the protein in a non-functional state that is less susceptible to the adaptive mutations that drive resistance to active-state inhibitors.

This approach, well-validated in other oncology settings, represents a paradigm shift for myelofibrosis and provides a mechanistic basis for the disease-modifying activity observed in the Phase I data.

Phase I Trial Design

The Phase I study enrolled 23 patients with relapsed or refractory myelofibrosis, each of whom had received and failed at least one prior JAK inhibitor. The decision to conduct the initial human study in this heavily pre-treated population, rather than treatment-naïve patients, underscores both the unmet need in this setting and the confidence Ajax and Lilly had in the drug’s preclinical profile.

Key Clinical Findings

Results across three primary endpoints exceeded historical benchmarks for second-line therapy:

• Spleen Volume Reduction: Seventy percent of evaluable patients achieved a reduction in spleen volume of 35% or greater (SVR35), the regulatory benchmark for spleen response. This compares favourably to published SVR35 rates of 0–32% with available second-line agents, representing a meaningful improvement in a population with historically limited spleen response.
• Symptom Burden Reduction: By Week 12, 70% of patients experienced at least a 50% reduction in total symptom score (TSS50), encompassing fatigue, bone pain, and night sweats. Symptom control of this magnitude in refractory patients is uncommon with current therapeutic options.
• Molecular Response: More than one-third of patients demonstrated a reduction of at least 50% in mutant allele burden by Week 24, indicating that the drug is actively eliminating malignant cells rather than merely suppressing their signalling. Durable molecular responses of this depth have not been reported with first-generation JAK inhibitors and suggest disease-modifying potential.

Safety and Tolerability

The principal treatment-related adverse event was anaemia, consistent with the known haematological toxicity of JAK pathway inhibition and confounded by the baseline anaemia present in many trial participants. Critically, the overall safety profile was sufficiently predictable and manageable that no patient discontinued treatment due to drug-related toxicity — a notable finding in a population with compromised bone marrow reserve and limited physiological tolerance.

Strategic Implications for Eli Lilly

The Ajax acquisition, completed in late 2025, was widely viewed as a premium-priced bet on a novel mechanistic hypothesis. The Phase I data validate that hypothesis and provide a clear path forward.

Jake Van Naarden, Lilly's head of oncology business development, indicated that the strength of the efficacy and safety data supports proceeding directly to dose selection for the next phase of clinical development. If those results confirm the Phase I signal, AJ1-11095 would be positioned as a best-in-class treatment for relapsed/refractory myelofibrosis, with potential expansion into earlier lines of therapy.

Lilly enters this development phase from a position of financial strength, underpinned by the commercial success of its GLP-1 receptor agonist portfolio. The company has the capital to support the global infrastructure required for a competitive multi-phase haematology programme and the commercial launch that would follow a positive outcome.

Outlook

While Phase I data must be interpreted with appropriate caution — given the small sample size and single-arm design — the breadth of the clinical signal is uncommon at this stage of development. Improvements spanning spleen volume, symptom burden, and molecular response, all observed simultaneously, will have the haematology community watching closely as Lilly advances the programme toward later-stage trials.

Should the programme succeed, AJ1-11095 would represent not only a commercially significant asset for Lilly, but a meaningful clinical advance for patients with myelofibrosis — a disease in which durable remission has long remained an elusive goal.

The EHA Annual Meeting is Europe’s premier haematology congress, bringing together clinicians, researchers, and industry representatives to present and discuss the latest advances in blood disorders. The 2026 meeting was held in Stockholm, Sweden.